Posts

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress – Eikon Therapeutics Clinical Pipeline Updates at ESMO 26 Congress in Madrid, Spain

on
Eikon Therapeutics has had seven abstracts accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. The abstracts cover updates across Eikon’s clinical pipeline, including EIK1001, EIK1003, EIK1004, and EIK1005. Presentations include updated Phase 2 data from TeLuRide-005 (EIK1001 plus pembrolizumab and chemotherapy in stage IV NSCLC), Phase 1/2 data for PARP1 inhibitors EIK1003 and EIK1004, and initial safety and pharmacokinetic data for the Werner helicase inhibitor EIK1005. Sources: Eikon Therapeutics Announces Seven Abstracts Accepted ... Eikon Therapeutics (EIKN) FDA Approvals Eikon Therapeutics (EIKN) Stock Price, News & Analysis Eikon Therapeutics (EIKN) News Today Eikon Therapeutics ASCO 2026 abstracts on key cancer ... Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025

Samsung Biologics Expands into Peptide API Manufacturing with $1.8B PolyPeptide Acquisition

on

Belite Bio Reports Additional Positive Secondary Endpoint Data from Phase 3 Tinlarebant Trial in Stargardt Disease Type 1 at ASRS 2026

on

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on

A rising tide scenario: Why other Big Pharmas could follow Lilly into psychedelics

on

Dimerix acquires kidney injury drug DMX-652 from Mission Therapeutics as Arpeggio appears to wind down acute kidney program

on

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador

on

Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections

on

Takeda's zasocitinib proves top-notch for difficult-to-treat psoriasis in Phase 3 update

on

BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields

on

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on